IL172762A0 - Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor - Google Patents

Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Info

Publication number
IL172762A0
IL172762A0 IL172762A IL17276205A IL172762A0 IL 172762 A0 IL172762 A0 IL 172762A0 IL 172762 A IL172762 A IL 172762A IL 17276205 A IL17276205 A IL 17276205A IL 172762 A0 IL172762 A0 IL 172762A0
Authority
IL
Israel
Prior art keywords
octan
oxazolidin
azabicyclo
spiro
affinity
Prior art date
Application number
IL172762A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Chang Hui Fang
Phillips Eilion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Chang Hui Fang, Phillips Eilion filed Critical Astrazeneca Ab
Publication of IL172762A0 publication Critical patent/IL172762A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL172762A 2003-07-08 2005-12-22 Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor IL172762A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48552303P 2003-07-08 2003-07-08
PCT/GB2004/002904 WO2005005435A1 (en) 2003-07-08 2004-07-06 Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Publications (1)

Publication Number Publication Date
IL172762A0 true IL172762A0 (en) 2006-04-10

Family

ID=34062082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172762A IL172762A0 (en) 2003-07-08 2005-12-22 Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Country Status (17)

Country Link
US (1) US7514567B2 (enExample)
EP (1) EP1654264A1 (enExample)
JP (1) JP2007516200A (enExample)
KR (1) KR20060057569A (enExample)
CN (1) CN1829721A (enExample)
AR (1) AR045040A1 (enExample)
AU (1) AU2004255920B2 (enExample)
BR (1) BRPI0412382A (enExample)
CA (1) CA2531510A1 (enExample)
IL (1) IL172762A0 (enExample)
MX (1) MXPA06000231A (enExample)
NO (1) NO20060612L (enExample)
NZ (1) NZ545132A (enExample)
SA (1) SA04250212B1 (enExample)
TW (1) TW200524942A (enExample)
WO (1) WO2005005435A1 (enExample)
ZA (1) ZA200600154B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524208A (ja) * 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021337A1 (en) * 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
JP2010505844A (ja) * 2006-10-03 2010-02-25 ガレオン・フアーマシユーチカルズ・インコーポレーテツド S−ニトロソチオール化合物および関連誘導体
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CA2730844A1 (en) * 2008-07-17 2010-01-21 Thomas Bretschneider Heterocyclic compounds used as pesticides
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UA107791C2 (en) * 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
EP2470516A1 (en) * 2009-08-27 2012-07-04 Yeda Research and Development Co. Ltd. Oligo- and polyfurans, preparation and uses thereof
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN103119034B (zh) * 2010-04-16 2016-08-03 拜耳知识产权有限责任公司 作为害虫防治剂的杂环化合物
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
EA201300160A1 (ru) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
AU2001241056A1 (en) 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs

Also Published As

Publication number Publication date
AU2004255920A1 (en) 2005-01-20
US20060154945A1 (en) 2006-07-13
TW200524942A (en) 2005-08-01
MXPA06000231A (es) 2006-04-11
ZA200600154B (en) 2007-04-25
BRPI0412382A (pt) 2006-09-19
WO2005005435A1 (en) 2005-01-20
EP1654264A1 (en) 2006-05-10
US7514567B2 (en) 2009-04-07
SA04250212B1 (ar) 2009-08-11
CN1829721A (zh) 2006-09-06
KR20060057569A (ko) 2006-05-26
JP2007516200A (ja) 2007-06-21
NZ545132A (en) 2009-07-31
CA2531510A1 (en) 2005-01-20
AU2004255920B2 (en) 2008-05-15
AR045040A1 (es) 2005-10-12
NO20060612L (no) 2006-04-06

Similar Documents

Publication Publication Date Title
AU2003212296A1 (en) Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
IL225968A0 (en) 1- Aza-bicyclo [3.3.1] nonanes
PT1725567E (pt) Derivados espirocíclicos de ciclo-hexano com afinidade para o receptor orl-1
AP2213A (en) Muscarinic acetylcholine receptor antagonists.
AP1828A (en) Muscarinic Acetycholine receptor antagonists
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
AU3809999A (en) Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ZA200708490B (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrole
IL178241A0 (en) NOVEL 2 - (1 - AZA - BICYCLO [2.2.2] OCT - 3 - YL) - 2, 3 - DIHYDROISOINDOL - 1 - ONE /5, 6 - DIHYDRO - FURO [2, 3 - c] PYRROL - 4 - ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
DE69915603D1 (de) Imidazo[1,2-a]pyridine als mittel zum binden des peripheralen benzodiazepin-rezeptors
IL183603A0 (en) Nicotinic acetylcholine receptor ligands
AP2006003575A0 (en) Muscarinic acetylcholine receptor antagonists.
AU2003202727A1 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ZA200803821B (en) Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
GB2446080B (en) A novel Pyrrolo [2,1-C][1,4] benzodiazepine hybrid and a process for the preparation thereof
AU1542000A (en) Seat track with zero chuck lock
EP1545508A4 (en) 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
HK1089162A (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
ZA991411B (en) Substituted imidazo [1,2-A:3,4A']diquinolinylium interleukin-8 receptor antagonist.
AU4564100A (en) Bicycle with passenger seat
HK1101636A (en) Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor